T1	Pharmacological_substance 9 25	Propylthiouracil
N1000 	Reference T1 MeSH:D011441	Propylthiouracil
T2	Disorder 34 54	cutaneous vasculitis
N1 	Reference T2 UMLS:C0262988	cutaneous vasculitis
T3	Pharmacological_substance 80 96	propylthiouracil
N1001 	Reference T3 MeSH:D011441	propylthiouracil
T4	Pharmacological_substance 101 112	methimazole
N1002 	Reference T4 MeSH:D008713	methimazole
T6	Disorder 289 309	cutaneous vasculitis
N2 	Reference T6 UMLS:C0262988	cutaneous vasculitis
T7	Pharmacological_substance 357 373	antithyroid drug
N1003 	Reference T7 MeSH:D013956	antithyroid drug
T8	Disorder 402 422	cutaneous vasculitis
N3 	Reference T8 UMLS:C0262988	cutaneous vasculitis
T9	Pharmacological_substance 448 464	propylthiouracil
N1004 	Reference T9 MeSH:D011441	propylthiouracil
T5	Pharmacological_substance 224 234	thionamide
N1005 	Reference T5 MeSH:C005896	thionamide
N1006 	Reference T5 MeSH:C009469	thionamide
N1007 	Reference T5 MeSH:C034609	thionamide
T12	Disorder 57 76	Cutaneous reactions
T13	Disorder 139 195	Generalized maculopapular and papular purpuric eruptions
N4 	Reference T13 UMLS:C0151882	Generalized maculopapular and papular purpuric eruptions
T14	Disorder 243 252	reactions
T17	Subject 264 274	3 patients
T20	Manner_cue 330 337	serious
T21	Subject 122 137	3%-5% of adults
